Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | MLYCD | O95822 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25007284 | 1.00 | HTT (0.50) | HTTMEN1KMT2APKMSMN1; SMN2 | |
| SCHEMBL21555502 | 0.98 | HTT (0.49) | HTTMEN1KMT2APKMSMN1; SMN2 | |
| SCHEMBL20366360 | 0.97 | HTT (0.48) | HTTMEN1KMT2APKMSMN1; SMN2 | |
| SCHEMBL18937752 | 0.97 | PKM (0.48) | HTTMEN1KMT2APKMSMN1; SMN2 | |
| SCHEMBL18610658 | 0.94 | HTT (0.48) | HTTMEN1KMT2APKMSMN1; SMN2 | |
| SCHEMBL24858435 | 0.90 | SMN1; SMN2 (0.46) | HTTMEN1KMT2APKMSMN1; SMN2 | |
| SCHEMBL18409015 | 0.87 | SMN1; SMN2 (0.46) | HTTMEN1KMT2APKMSMN1; SMN2 | |
| SCHEMBL21713229 | 0.85 | PKM (0.49) | HTTMEN1KMT2APKMSMN1; SMN2 | |
| SCHEMBL19687553 | 0.85 | L3MBTL1 (0.50) | MEN1KMT2A | |
| SCHEMBL25696570 | 0.85 | L3MBTL1 (0.46) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9975893-B2 | Pyrazolo[3,4-c]pyridine derivatives | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2018-05-22 | — | — | US | disclosed |
| US-9920075-B2 | Triazolopyridine and triazolopyrimidine inhibitors of myeloperoxidase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-03-20 | — | — | US | disclosed |
| US-20170291896-A1 | PYRAZOLO[3,4-C]PYRIDINE DERIVATIVES | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2017-10-12 | — | — | US | disclosed |
| US-20170247396-A1 | TRIAZOLOPYRIDINE AND TRIAZOLOPYRIMIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL MYERS SQUIBB CO (US) | 2017-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170291896-A1 | PYRAZOLO[3,4-C]PYRIDINE DERIVATIVES | F11, TFPI, F2 | HTT 3756/4885MEN1 1111/4885KMT2A 4066/4885 |
| US-20170247396-A1 | TRIAZOLOPYRIDINE AND TRIAZOLOPYRIMIDINE INHIBITORS OF MYELOPEROXIDASE | EPX, MPO, SERPINB1 | HTT 4604/4885MEN1 4280/4885KMT2A 1779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.